학술논문
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial
Document Type
Article
Author
Michallet, A.-S.; Dilhuydy, M.-S.; Subtil, F.; Rouille, V.; Cartron, G.; Mahe, B.; Laribi, K.; Villemagne, B.; Salles, G.; Tournilhac, O.; Delmer, A.; Portois, C.; Pegourie, B.; Leblond, V.; Nguyen-Khac, F.; Tomowiak, C.; de Guibert, S.; Orsini, F.; Banos, A.; Carassou, P.; Fornecker, L.M.; Ysebaert, L.; Dartigeas, C.; Truchan Graczyk, M.; Vilque, J.P.; Aurran, T.; Letestu, R.; Cymbalista, F.; Lepretre, S.; Lévy, V.; Le Garff-Tavernier, M.; Aanei, C.; Ticchioni, M.; Feugier, P.
Source
In: The Lancet Haematology . (The Lancet Haematology, September 2019, 6(9):e470-e479)
Subject
Language
English
ISSN
23523026